Published in Antiviral Res on July 23, 2011
Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev (2012) 1.31
Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS One (2012) 1.24
Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice. PLoS Pathog (2013) 1.09
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. PLoS Pathog (2013) 1.00
TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. J Virol (2014) 0.99
Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res (2013) 0.98
The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes. J Mol Genet Med (2013) 0.96
Characteristics of human infection with avian influenza viruses and development of new antiviral agents. Acta Pharmacol Sin (2013) 0.94
Influenza A virus proteins NS1 and hemagglutinin along with M2 are involved in stimulation of autophagy in infected cells. J Virol (2013) 0.88
Activation of influenza A viruses by host proteases from swine airway epithelium. J Virol (2013) 0.81
Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus. J Prev Med Hyg (2014) 0.81
The Proteolytic Activation of (H3N2) Influenza A Virus Hemagglutinin Is Facilitated by Different Type II Transmembrane Serine Proteases. J Virol (2016) 0.78
Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia. Cell Mol Immunol (2016) 0.78
Synthesis of novel N-acetylneuraminic acid derivatives as substrates for rapid detection of influenza virus neuraminidase. Carbohydr Res (2012) 0.77
Influenza virus-host interactomes as a basis for antiviral drug development. Curr Opin Virol (2015) 0.77
Influenza virus pathogenicity regulated by host cellular proteases, cytokines and metabolites, and its therapeutic options. Proc Jpn Acad Ser B Phys Biol Sci (2015) 0.76
Inhibition of influenza virus infection and hemagglutinin cleavage by the protease inhibitor HAI-2. Biochem Biophys Res Commun (2014) 0.76
The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice. PLoS One (2015) 0.75
Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics (2017) 0.75
Coronavirus and influenza virus proteolytic priming takes place in tetraspanin-enriched membrane microdomains. J Virol (2015) 0.75
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med (2000) 8.46
Activation of influenza A viruses by trypsin treatment. Virology (1975) 8.07
The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46
GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology (1995) 5.34
Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J (1992) 5.05
Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology (1976) 4.85
Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A (1998) 4.33
Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol (1999) 4.32
Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature (1992) 4.16
Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr (2000) 4.08
Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 3.77
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Influenza virus proteins. I. Analysis of polypeptides of the virion and identification of spike glycoproteins. Virology (1970) 3.58
The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci U S A (2001) 3.43
Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol (1971) 3.33
The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. Virology (1979) 3.25
Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science (2001) 3.08
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis (1992) 3.07
Presence of murine leukemia virus envelope proteins gp70 and p15(E) in a common polyprotein of infected cells. J Virol (1976) 2.91
Inhibition of glycoprotein biosynthesis of influenza virus by D-glucosamine and 2-deoxy-D-glucose. Virology (1972) 2.84
Two independent targeting signals in the cytoplasmic domain determine trans-Golgi network localization and endosomal trafficking of the proprotein convertase furin. EMBO J (1995) 2.76
Glycosphingolipids of plasma membranes of cultured cells and an enveloped virus (SV5) grown in these cells. Proc Natl Acad Sci U S A (1970) 2.73
Influenza viruses cause hemolysis and fusion of cells. Virology (1981) 2.73
Glycolipid content of vesicular stomatitis virus grown in baby hamster kidney cells. J Virol (1971) 2.68
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis (1994) 2.52
The proteins of the parainfluenza virus SV5. 1. Separation of virion polypeptides by polyacrylamide gel electrophoresis. Virology (1969) 2.50
Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology (1994) 2.48
Lipids of plasma membranes of monkey and hamster kidney cells and of parainfluenza virions grown in these cells. Virology (1969) 2.48
Molecular biology and evolution of filoviruses. Arch Virol Suppl (1993) 2.45
Interactions of Marburg virus nucleocapsid proteins. Virology (1998) 2.37
The proteins of the parainfluenza virus SV5. II. The carbohydrate content and glycoproteins of the virion. Virology (1970) 2.37
Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle. Virus Res (1992) 2.29
Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol (1996) 2.26
Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol (1979) 2.25
How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res (1998) 2.25
Pause on avian flu transmission research. Science (2012) 2.24
Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology (2000) 2.21
Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein. J Virol (1994) 2.17
Proteolytic activation of the influenza virus hemagglutinin: The structure of the cleavage site and the enzymes involved in cleavage. Virology (1981) 2.13
Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis (1997) 2.12
Glycosylation and oligomerization of the spike protein of Marburg virus. Virology (1991) 2.11
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrate moiety. J Virol (1997) 2.09
Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J Virol (2000) 2.09
Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J (2000) 2.08
Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones. Biochimie (1994) 2.07
Comparison of competitive and indirect enzyme-linked immunosorbent assays for detection of bluetongue virus antibodies in serum and whole blood. J Clin Microbiol (1987) 2.07
Association of influenza virus proteins with cytoplasmic fractions. Virology (1974) 2.00
Activation of precursors to both glycoporteins of Newcastle disease virus by proteolytic cleavage. Virology (1977) 2.00
Expression of the influenza virus haemagglutinin in insect cells by a baculovirus vector. EMBO J (1986) 1.98
Studies on the adaptation of influenza viruses to MDCK cells. EMBO J (1984) 1.98
Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol (1980) 1.97
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
The function of the neuraminidase in membrane fusion induced by myxoviruses. Virology (1980) 1.97
Role of Staphylococcus protease in the development of influenza pneumonia. Nature (1987) 1.96
Temperature-sensitive mutants of respiratory syncytial virus. J Virol (1969) 1.94
Influenza C virus uses 9-O-acetyl-N-acetylneuraminic acid as a high affinity receptor determinant for attachment to cells. J Biol Chem (1986) 1.92
Infection and activation of monocytes by Marburg and Ebola viruses. J Virol (2001) 1.90
Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J (2001) 1.90
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
An electron microscopic study of the presence or absence of neuraminic acid in enveloped viruses. Virology (1970) 1.88
The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch Virol Suppl (1999) 1.87
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis (1997) 1.86
The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr (2000) 1.85
Marburg virus gene 4 encodes the virion membrane protein, a type I transmembrane glycoprotein. J Virol (1993) 1.85
Biosynthesis and role of filoviral glycoproteins. J Gen Virol (2001) 1.84
Mutations at the cleavage site of the hemagglutinin after the pathogenicity of influenza virus A/chick/Penn/83 (H5N2). Virology (1989) 1.81
Marburg and Ebola viruses. Adv Virus Res (1996) 1.81
Inhibition of glycosylation of the influenza virus hemagglutinin. J Virol (1974) 1.81
Maturation of the trans-Golgi network protease furin: compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation. J Cell Biol (1994) 1.80
Hemagglutinin activation of pathogenic avian influenza viruses of serotype H7 requires the protease recognition motif R-X-K/R-R. Virology (1992) 1.79
Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein. J Virol (2000) 1.79
Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus. J Mol Biol (2000) 1.79
Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis (1994) 1.78
The receptor-destroying enzyme of influenza C virus is neuraminate-O-acetylesterase. EMBO J (1985) 1.76
Adenovirus infections in young children. Pediatrics (1985) 1.76
The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J Gen Virol (1995) 1.76
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
Fusion between cell membrane and liposomes containing the glycoproteins of influenza virus. Virology (1980) 1.73
Release of viral glycoproteins during Ebola virus infection. Virology (1998) 1.73
A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis (1995) 1.68
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Post-translational glycosylation of coronavirus glycoprotein E1: inhibition by monensin. EMBO J (1982) 1.67
Cytomegalovirus pneumonia in two infants recently adopted from China. Clin Infect Dis (1999) 1.65
Site-specific mutagenesis identifies three cysteine residues in the cytoplasmic tail as acylation sites of influenza virus hemagglutinin. J Virol (1991) 1.65
The natural history of human immunodeficiency virus 1 infection in Haitian infants. Pediatr Infect Dis J (1999) 1.64
Carbohydrates of influenza virus. Structural elucidation of the individual glycans of the FPV hemagglutinin by two-dimensional 1H n.m.r. and methylation analysis. EMBO J (1985) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology (1998) 1.62
Neuraminidase is essential for fowl plague virus hemagglutinin to show hemagglutinating activity. Virology (1995) 1.62
Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun (1982) 1.61
Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis (1982) 1.61
Proteolytic processing of human cytomegalovirus glycoprotein B (gpUL55) is mediated by the human endoprotease furin. Virology (1995) 1.60
A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol (2001) 1.59
Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol (1985) 1.59